Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Payers and patient compliance will determine winners as Incivek and Victrelis hit HCV

This article was originally published in Scrip

Executive Summary

While data on Vertex/Janssen's Incivek (telaprevir) published on 27 June in the New England Journal of Medicine provided little new insight into the drug's efficacy beyond what was already known from the EASL meeting in April, the companies believe that they have the edge over Merck's boceprevir in winning round physicians to using their drug in both naive and previously-treated patient groups. However, as pointed out in a recent survey, the pattern of prescribing for the two HCV NS3/4A protease inhibitors is likely to be heavily influenced by the behaviours of payer organisations, many of which seem unwilling to reimburse either drug in treatment-naive patients.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

SC013539

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel